ImageneBio, formed by merging Ikena Oncology and Inmagene Biopharmaceuticals, has recalibrated its growth trajectory around the clinical advancement of its lead candidate IMG-007. Despite continued operating losses, the company improved profitability metrics year over year and preserved robust liquidity, evidenced by a current ratio exceeding 12x at fiscal year-end 2025. Capital deployment remained conservative with minimal capex and modest share repurchases, aligning with development-stage priorities. Regulatory and integration risks persist as critical variables shaping the company's outlook toward forthcoming clinical milestones.